NEW
YORK, Jan. 30, 2023 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, will participate at the BTIG MedTech, Digital Health,
Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16.
Delcath CEO, Gerard Michel will
be conducting one-on-one meetings. To request a one-on-one meeting
please contact your BTIG representative with interest.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company's proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the
PHP system is being developed under the tradename HEPZATO™ KIT
(melphalan hydrochloride for injection/Hepatic Delivery System), or
HEPZATO, for the treatment of patients with unresectable
hepatic-dominant metastatic ocular melanoma (mOM), also known as
metastatic uveal melanoma (mUM) and is considered a combination
drug and device product regulated as a drug by the United States
Food and Drug Administration (FDA).
In Europe, the PHP system is
now regulated as a Class lll medical device and is approved for
sale under the trade name CHEMOSAT Hepatic Delivery System for
Melphalan, or CHEMOSAT, where it has been used at major medical
centers to treat a wide range of cancers of the liver.
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-at-the-btig-medtech-digital-health-life-sciences--diagnostic-tools-conference-on-february-14-to-16-301733027.html
SOURCE Delcath Systems, Inc.